Pharmaceutical Technology-02-02-2002
Pharmaceutical Technology
Using Earned-Value Analysis to Better Manage Projects
February 01, 2002
Contract Services
26
2
EVA takes into account a project's schedule and budget to determine the true cost performance.
Microbial Bioburden on Oral Solid Dosage Forms
February 01, 2002
Articles
26
2
Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part I
February 01, 2002
Articles
26
2
A combination of security technologies, infrastructures, and cryptographic product-services families can help companies satisfy the requirements of 21 CFR Part 11.
Modernizing Pharmaceutical Manufacturing
February 01, 2002
Columns
26
2
FDA's Center for Drug Evaluation and Research is driving efforts toward creating initiatives to streamline regulatory processes, speed up drug production, and reduce costs.
The Role of Computational Fluid Dynamics in the Pharmaceutical Industry
February 01, 2002
Articles
26
2
Computational fluid dynamics can be a valuable tool for analyzing the efficiencies and performances of process equipment, which can lead to potential cost savings.
Available Guidance and Best Practices for Conducting Forced Degradation Studies
February 01, 2002
Articles
26
2
Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
Outsourcing Outlook
February 01, 2002
Contract Services
26
2
The author discusses current economic times and conditions for large pharmaceutical companies.
Effect of Formulation and Process Variables on Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug
February 01, 2002
Articles
26
2
By optimizing formulation and process varibles, pellets can be prepared that can release a poorly soluble drug for 12-24 h following zero-order kinetics.